Peptide Research: IGF-1 LR3 – Studies, Research Use, and Scientific Background

What is IGF-1 LR3?

IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a synthetic analog of IGF-1, engineered to have an extended half-life and increased bioactivity in laboratory research. It is widely studied in preclinical models for its effects on muscle cell growth, protein synthesis, tissue repair, and metabolic function.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Muscle Growth and Regeneration: Laboratory studies have demonstrated that IGF-1 LR3 significantly stimulates muscle cell differentiation, myogenesis, and protein synthesis in animal and in vitro models.
  Florini et al., 1996
• Metabolic and Cellular Research: Preclinical studies highlight IGF-1 LR3’s role in tissue regeneration, glucose metabolism, and research models of growth and repair.
  Beck et al., 2003

Laboratory Research Applications

• Studies of muscle growth, myogenesis, and tissue repair
• Research on protein synthesis and cellular proliferation
• Preclinical models of metabolic function and glucose regulation
• Investigation of growth factor signaling pathways

Mechanism of Action (in Research Context)

IGF-1 LR3 binds to IGF-1 receptors on cell membranes, stimulating intracellular signaling that promotes cellular growth, division, and differentiation. The LR3 modification extends its half-life, increasing its bioavailability and effectiveness in laboratory experiments compared to native IGF-1.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of IGF-1 LR3:

• Common Dose Range (animal studies): 10–100 mcg/kg, administered subcutaneously or intramuscularly
• Duration: Typically 7–21 days, depending on experimental protocol